A Review on Fungal Infections and Their Treatments in Children with Renal Disorders
Journal of Pediatric Nephrology,
Vol. 5 No. 1 (2017),
6 June 2017
,
Page 1-9
https://doi.org/10.22037/jpn.v5i1.17477
Abstract
Fungal infections especially invasive ones (IFI), now are among well known and hard to manage problems in various kidney diseases in children. Various databases including pubmed, scopus, ovid and Web of Science Core Collection were looked for keywords including antifungals, fungal infections, kidney diseases Since 1990 to 2017. Renal side effects were looked using the site WWW.DRUG.COM as well. For common cases with Identified Pathogens Infectious diseases society of America (IDSA) recommendations for antifungal therapy as the most acceptable plan has been summarized at the end of article; specific therapeutic issues have been also discussed in their sections.
Keywords: Fungal Infections; Renal Diseases; Acute Kidney Injury; Hemodialysis; CAPD, Kidney Transplantation.How to Cite
References
Gandhi BV, Bahadur MM, Dodeja H, Aggrwal V, Thamba A, Mali M.Systemic fungal infections in renal diseases. J Postgrad Med 2005 Vol 51 Suppl 1,530-536.
Khan A, El-Charabaty E, El-Sayegh S. Fungal Infections in Renal Transplant Patients. J Clin Med Res. 2015;7(6):371-378.
June- Mug sung, et al. Candidaemia in patients with dialysis dependent ARF etiology, predisposing and prognostic factors. NDT 2001;16:2348-56.
Nateghian A, Sedighi M. In-hospital Outcome and Main Determinants of Candida Septicemia in Children Admitted to Neonatal and Pediatric Intensive Care Units. ijca. 2016; 2 (4) :20-24
URL: http://ijca.iums.ac.ir/article-1-82-en.html
Weath H, Margensen P. Extracorporeal shock wave lithotripsy of a kidney stone complicated with candida albicans septicemia and endophthalmitis: case report. Scand J Urol Nephrol 1990;24:81.
Rex JH, Bennette TG. Candidaemia study group and the national institute of Allegy and infectious disease mycoses study group. A randomized trial company Fluconazole with Ampho B for treatment of candidaemia in patients without neutropenia. NETM 1994;331:1325-30.
Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, Freifeld A, Anaissie EJ, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-ssociated Infection Surveillance Network (TRANSNET). Clin Infect Dis. 2010;50(8):1101-1111.
Serefhanoglu K, Timurkaynak F, Can F, Cagir U, Arslan H, Ozdemir FN. Risk factors for candidemia with non-albicans Candida spp. in intensive care unit patients with end-stage renal disease on chronic hemodialysis. J Formos Med Assoc. 2012 Jun;111(6):325-32. doi: 10.1016/j.jfma.2011.03.004.
Irimie, M; Tataru, A; Oanta, A; Moga, M.
In vitro susceptibility of dermatophytes isolated from patients with end-stage renal disease; a case-control study.Journals@Ovid Full TextMycoses. 57(3):129-134, March 2014.
Matuszkiewicz-Rowinska J. Update on fungal peritonitis and its treatment. Perit Dial Int. 2009 Feb;29 Suppl 2:S161-5.
Wang AY, Yu AW, Li PK, Lam PK, Leung CB, Lai KN, Lui SF. Factors predicting outcome of fungal peritonitis in peritoneal dialysis: analysis of a 9-year experience of fungal peritonitis in a single center. Am J Kidney Dis. 2000 Dec;36(6):1183-92.
Kumar KV, Mallikarjuna HM, S. Jayanthi G. Fungal peritonitis in continuous ambulatory peritoneal dialysis: The impact of antifungal prophylaxis on patient and technique outcomes. Indian J Nephrol. 2014 Sep-Oct; 24(5): 297–301. doi: 10.4103/0971-4065.133005.
Hooman N, Madani A, Sharifian Dorcheh M, Mahdavi A, Derakhshan A, Gheissari A,et al. Fungal Peritonitis in Iranian Children on Continuous Ambulatory Peritoneal Dialysis,A National Experience. IJKD 2007;1:1-00.
Nadeau-Fredette AC, Bargman JM. CHARACTERISTICS AND OUTCOMES OF FUNGAL PERITONITIS IN A MODERN NORTH AMERICAN COHORT. Peritoneal Dialysis International, Vol. 35, pp. 78–84.doi: 10.3747/pdi.2013.00179.
Lee SH, Chiang SS, Hseih SJ, Shen HM. Successful treatment of fungal peritonitis with intracatheter antifungal retention. Adv Perit Dial. 1995;11:172–5.
Kam-Tao Li P, Szeto CC, Piraino B, Bernardini J, Figueiredo AE, Gupta A. ISPD GUIDELINES/RECOMMENDATIONS PERITONEAL DIALYSIS-RELATED INFECTIONS RECOMMENDATIONS: 2010 UPDATE. Peritoneal Dialysis International, Vol. 30, pp. 393–423.doi:10.3747/pdi.2010.00049.
Kiernan L, Kliger A, Gorban-Brennan N, Juergensen P,Tesin D, Vonesh E, et al. Comparison of continuous ambulatoryperitoneal dialysis-related infections with different “Y-tubing” exchange systems. J Am Soc Nephrol 1995;5:1835–8.
Sedlacek M, Cotter JG, Suriawinata AA, Kaneko TM,Zuckerman RA, Parsonnet J, et al. Mucormycosis peritonitis:more than 2 years of disease-free follow-up afterposaconazole salvage therapy after failure of liposomal amphotericin B. Am J Kidney Dis 2008; 51:302–6.
Fourtounas C, Marangos M, Kalliakmani P, Savidaki E,Goumenos DS, Vlachojannis JG. Treatment of peritoneal dialysis related fungal peritonitis with caspofungin plus amphotericin B combination therapy. Nephrol Dial Transplant 2006; 21:236–7.
Michael Green Marian G. Michaels. Infections in Pediatric Solid Organ Transplant Recipients. J Pediatric Infect Dis Soc (2012) 1 (2): 144-151.DOI:https://doi.org/10.1093/jpids/pir001.
Abbott KC, Hypolite I, Poropatich RK, Hshieh P, Cruess D, Hawkes CA, Agodoa LY, et al. Hospitalizations for fungal infections after renal transplantation in the United States. Transpl Infect Dis. 2001;3(4):203-211.
Wattier RL, Ramirez-Avila L. Pediatric Invasive Aspergillosis. J. Fungi 2016, 2, 19; doi:10.3390/jof2020019.
Gavalda J, Len O, San Juan R, Aguado JM, Fortun J,Lumbreras C, Moreno A, et al. Risk factors for invasive aspergillosis in solid-organ transplant recipients: a casecontrol study. Clin Infect Dis. 2005;41(1):52-59.
Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis.Clin Infect Dis. 2006;42(10):1417-1427.
De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis.2008;46(12):1813-1821.
Olga M. Klibanov; Ralph H. Raasch; John C. Rublein. Changes in Renal Function After Changes in Antifungal Drug Therapy .Am J Health Syst Pharm. 2004;61(1).
Bes DF, Rosanova MT, Sberna N, Arrizurieta E. Deoxycholate amphotericin B and nephrotoxicity in the pediatric setting. Pediatr Infect Dis J. 2014 Aug;33(8):e198-206. doi: 10.1097/INF.0000000000000299.
Wiley JM, Seibel NL, Walsh TJ. Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections. Pediatr Infect Dis J. 2005 Feb;24(2):167-74.
Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis. 2000 Nov;31(5):1155-63. Epub 2000 Nov 7.
Dutta A, Palazzi DL. Risk factors of amphotericin B toxicty in the nonneonatal pediatric population. Pediatr Infect Dis J. 2012 Sep;31(9):910-4. doi: 10.1097/INF.0b013e31825d649a.
Goldman RD, Koren G. Amphotericin B nephrotoxicity in children. J Pediatr Hematol Oncol. 2004 Jul;26(7):421-6.
WOOD JE, MAHNENSMITH MP; MAHNENSMITH RL, PERAZELLA MA. Intradialytic Administration of Amphotericin B:Clinical Observations on Efficacy and Safety. Am J Med Sci 2004;327(1):5–8.
Cannon JP, Garey KW, Danziger LH. A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations. Pharmacotherapy. 2001 Sep;21(9):1107-14.
Saliba F, Dupont B. Renal impairment and amphotericin B formulations in patients with invasive fungal infections. Med Mycol. 2008 Mar;46(2):97-112. doi: 10.1080/13693780701730469.
Barrett JP, Vardulaki KA, Conlon C, Cooke J, Daza-Ramirez P, Evans EG et al. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther. 2003 May;25(5):1295-320.
Alvarez-Lerma F, Soriano MC, Rodríguez M, Catalán M, Llorente AM, Vidart N. Impact of liposomal amphotericin B on renal function in critically ill patients with renal function impairment. Rev Esp Quimioter. 2012 Sep;25(3):206-15.
Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis. 2003;36(5):630-637.
Romero AJ, Le Pogamp P, Nilsson LG, Wood N. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther.2002;71(4):226-234.
Lilly CM, Welch VL, Mayer T, Ranauro P, Meisner J, Luke DR. Evaluation of intravenous voriconazole in patients with compromised renal function. BMC Infect Dis. 2013 Jan 16;13:14. doi: 10.1186/1471-2334-13-14.
Allen UD. Antifungal agents for the treatment of systemic fungal infections in children.Paediatr Child Health 2010;15(9):603-8.
Mathis AS; DiRenzo T; Friedman G; Kaplan B; Adamson R.
SEX AND ETHNICITY MAY CHIEFLY INFLUENCE THE INTERACTION OF FLUCONAZOLE WITH CALCINEURIN INHIBITORS 12. Journals@Ovid.2001;71(8):1069-1075.
Shin GT, Yim H, Park J, Kim H "Membranous nephropathy associated with fluconazole treatment." Am J Kidney Dis 49 (2007): 318-22.
Moore JN, HealyJR, ,Kraft WK. Pharmacologic and clinical evaluation of posaconazole. Expert Rev Clin Pharmacol. 2015 May; 8(3): 321–334.Doi: 10.1586/17512433.2015.1034689.
Van Burik JA, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH, Vesole DH, Bunin N, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis.2004;39(10):1407-1416.
Hebert MF, Smith H E. , Marbury, TS, Swan SK et al. Pharmacokinetics of Micafungin in Healthy Volunteers, Volunteers With Moderate Liver Disease, and Volunteers With Renal Dysfunction.Journals@Ovid journal of Clinical Pharmacology. 45(10):1145-1152, October 2005.
Muilwijk E, Lempers V, Burger D,Warris A, Pickkers P, Aarnoutse R et al. Impact of special patient populations on the pharmacokinetics of echinocandins.Expert Rev. Anti Infect. Ther. 13(6), 799–815 (2015)
Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB, Sable CA, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis. 2004;39(11):1563-1571.
Dowell ,J,Stogniew M,Krause D .Anidulafungin dosage adjustments are not required for patients with hepatic and/or renal impairment [abstract P-1222]Program and abstracts of the 13th European Congress of Clinical Microbiology and Infectious Diseases (Glasgow, UK)2003,Basel, Switzerland .European Society of Clinical Microbiology and Infectious Diseases).
Lestner JM, Versporten A, Doerholt K, Warris A, Roilides E, Sharland M, Bielicki J, Goossens H, ARPEC Project Group. 2015. Systemic antifungal prescribing in neonates and children: outcomes from the Antibiotic Resistance and Prescribing in European Children (ARPEC) study. Antimicrob Agents Chemother .59:782–789. doi:10.1128/AAC.04109-14.
Pappas PG Kauffman CA,Andes DR, Clancy CJ, Marr et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America,Clinical Infectious Diseases® 2016;62(4):e1–50.
Patterson TF, Thompson GR Denning DWFishman JA Hadley S et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America Clinical Infectious Diseases® 2016;63(4):e1–60.
- Abstract Viewed: 602 times
- PDF Downloaded: 331 times